Tag: Niraparib

FDA approves niraparib for treatment of recurrent ovarian cancer

Ovarian cancer is one of the more lethal cancers that women can develop. It is often associated with either inherent mutations in a woman’s own DNA, or mutations that develop within an ovarian cancer, that impairs the ability of your body to repair DNA breaks. PARP (poly ADP-ribose polymerase) inhibitors are oral medications that further… Read more »